NCT01827839View on ClinicalTrials.gov

Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine GSK1437173A in Adults With a Prior Episode of Herpes Zoster

PHASE3CompletedINTERVENTIONAL
Enrollment

96

Participants

Timeline

Start Date

June 10, 2013

Primary Completion Date

February 10, 2014

Study Completion Date

November 25, 2014

Conditions
Herpes Zoster
Interventions
BIOLOGICAL

Herpes Zoster vaccine (GSK1437173A)

2 doses administered intramuscularly in deltoid region of non-dominant arm.

Trial Locations (4)

620137

GSK Investigational Site, Yekaterinburg

656056

GSK Investigational Site, Barnaul

V3K 3P4

GSK Investigational Site, Coquitlam

H9R 4S3

GSK Investigational Site, Pointe-Claire

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT01827839 - Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine GSK1437173A in Adults With a Prior Episode of Herpes Zoster | Biotech Hunter | Biotech Hunter